Back

In vitro models for oncology

Biotrial provides preclinical oncology services designed to support biotech and pharmaceutical companies in advancing innovative cancer therapies from early discovery to IND-enabling stages.

Our in vitro and in vivo oncology platforms generate robust, reproducible, and translational data across a wide range of therapeutic modalities, including small molecules, biologics, antibody-drug conjugates, gene therapies, and cell-based immunotherapies.

Flexible biological platforms to support Oncology drug development

Biotrial supports oncology research by providing a broad selection of biological materials and experimental platforms, allowing sponsors to design in vitro studies that best reflect the biology of their therapeutic target.

Depending on the scientific objectives of the program, researchers can select the most appropriate cellular models and tumor systems, which can then be used across a range of functional, molecular, and genetic assays.

Our in vitro platform is designed to generate reliable mechanistic data, support early candidate selection, and guide the transition toward in vivo validation.

EXPLORE OUR PRECLINICAL SERVICES

Biological materials & experimental models

Biotrial provides access to a range of biological materials that can be selected depending on the indication, mechanism of action, and therapeutic modality under investigation.

Available biological systems include:

Cancer cell lines: well-characterized tumor models widely used for drug screening and mechanistic studies.
Primary tumor cells: derived from patient samples, offering models that better reproduce tumor heterogeneity and clinical biology.
2D cell culture systems: standardized platforms enabling reproducible high-throughput drug screening.
3D tumor culture models: including spheroids and multicellular systems that better reproduce tumor architecture, microenvironment interactions, and treatment resistance mechanisms.
Tumor-representative panels: collections of models representing multiple tumor subtypes, genetic backgrounds, or resistance profiles.

In vitro functional assay services

Using these biological models, Biotrial provides a range of functional assays designed to evaluate therapeutic activity and tumor cell responses.

Our functional assay services include:

Drug screening assays: to evaluate compound activity across selected tumor models and identify the most promising therapeutic candidates.
Cytotoxicity and potency assays: including EC50 determination, cell viability assays, and clonogenic assays to measure long-term effects on tumor proliferation.
Migration and invasion assays: used to investigate tumor aggressiveness and the ability of compounds to inhibit metastatic behavior.
Mechanism-of-action functional studies: designed to understand how investigational drugs affect cellular signaling pathways or immune interactions.
Customized assay development: tailored to specific therapeutic modalities such as CAR-T therapies, antibody-drug conjugates, or gene therapies.

These assays help sponsors evaluate compound efficacy, characterize dose-response relationships

Protein expression and cellular characterization services

Biotrial also provides protein expression and cellular characterization services to support deeper understanding of therapeutic mechanisms and biomarker identification.

Gene modification technologies
- Transfection techniques
- Viral infection systems
- CRISPR/Cas9 gene editing

Histology and immunohistochemistry: allowing visualization of protein expression and cellular structures within tumor models.
Multiparametric flow cytometry and cellular phenotyping : to analyze tumor and immune cell populations, and evaluate treatment-induced biological responses.
Tumor cell population characterization tests

These analyses generate mechanistic insights into drug activity.

Genetic and molecular analysis services

To complement functional and protein-level assays, Biotrial offers genetic and molecular characterization services supporting target validation and biomarker discovery.

Our capabilities include:

Gene expression profiling
- PCR / qPCR / ddPCR
- RNA sequencing (RNAseq)

Pathway analysis and biomarker discovery to identify molecular signatures associated with treatment response or resistance.

These genetic services enable mechanistic exploration of therapeutic targets and strengthen translational relevance between preclinical and clinical development.